MARK SCANLAN: Open Payments
NPI 1013933274 · SCOTTSBLUFF, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$800 in 59 payments from 10 companies in 2025. Trend: 2023 $628 · 2024 $866 · 2025 $800
Food & beverage: $800
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 24 | $303 |
| Teva Pharmaceuticals USA, Inc. | 22 | $240 |
| Janssen Pharmaceuticals, Inc | 4 | $66 |
| E.R. Squibb & Sons, L.L.C. | 3 | $57 |
| Lundbeck LLC | 1 | $26 |
| Neuronetics, Inc. | 1 | $24 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $22 |
| ABBVIE INC. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $19 |
Products named: ABILIFY MAINTENA, REXULTI, UZEDY, AUSTEDO XR, COBENFY, INVEGA SUSTENNA, NEUROSTAR TMS THERAPY SYSTEM, CAPLYTA.
Industry payments across NE — which companies pay providers there.
